EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudie

Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women

Linda-Gail Bekker iD, Moupali Das, Quarraisha Abdool Karim iD, Khatija Ahmed, Joanne Batting, William Brumskine, Katherine Gill, Ishana Harkoo, Manjeetha Jaggernath, Godfrey Kigozi, Noah Kiwanuka, Philip Kotze und 29 weitere

New England Journal of Medicine · 03.10.2024 · 391 (13) · 1179-1192

DOI: 10.1056/nejmoa2407001 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 03.10.2024. Verfasst von Linda-Gail Bekker und 40 weiteren Autor:innen. Beteiligte Einrichtung: From the Desmond Tutu HIV Centre (L.-G.B., K.G., G.N., Y.S.) and the Department of Medicine, Vuka Research Clinic (A.M.W.), University of Cape Town, …. Hauptthemen laut MEDLINE: Anti-HIV Agents, Emtricitabine, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination, HIV Infections. Die Arbeit wurde bisher 568-mal zitiert (Crossref) und nennt 41 Literaturangaben. Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsEmtricitabineEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationHIV InfectionsPre-Exposure ProphylaxisTenofovirAdolescentAdultFemaleHumansYoung AdultAdenineAdministration, OralDouble-Blind MethodDrug Administration ScheduleIncidenceInjections, SubcutaneousSouth AfricaUgandaInjection Site ReactionDrug Monitoring

Substanzen

AdenineAnti-HIV AgentsEmtricitabineemtricitabine tenofovir alafenamideEmtricitabine, Tenofovir Disoproxil Fumarate Drug CombinationTenofovir

Autor:innen und Institutionen

  • From the Desmond Tutu HIV Centre (L.-G.B., K.G., G.N., Y.S.) and the Department of Medicine, Vuka Research Clinic (A.M.W.), University of Cape Town, Cape Town, the Department of Epidemiology and Prevention, Centre for t…

ORCID-Profile: Linda-Gail Bekker, Quarraisha Abdool Karim, Leila E Mansoor

Förderung

  • Gilead Sciences

Zitieren

APA

Bekker, L. G., Das, M., Abdool Karim, Q., Ahmed, K., Batting, J., Brumskine, W., Gill, K., Harkoo, I., Jaggernath, M., Kigozi, G., Kiwanuka, N., Kotze, P., Lebina, L., Louw, C. E., Malahleha, M., Manentsa, M., Mansoor, L. E., Moodley, D., Naicker, V., …, & PURPOSE 1 Study Team (2024). Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. New England Journal of Medicine, 391(13), 1179-1192. https://doi.org/10.1056/nejmoa2407001

Vancouver

Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W, et al. Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women. New England Journal of Medicine. 2024;391(13):1179-1192. doi:10.1056/nejmoa2407001

BibTeX
@article{Bekker2024,
  author = {Bekker, Linda-Gail and Das, Moupali and Abdool Karim, Quarraisha and Ahmed, Khatija and Batting, Joanne and Brumskine, William and Gill, Katherine and Harkoo, Ishana and Jaggernath, Manjeetha and Kigozi, Godfrey and Kiwanuka, Noah and Kotze, Philip and Lebina, Limakatso and Louw, Cheryl E and Malahleha, Moelo and Manentsa, Mmatsie and Mansoor, Leila E and Moodley, Dhayendre and Naicker, Vimla and Naidoo, Logashvari and Naidoo, Megeshinee and Nair, Gonasagrie and Ndlovu, Nkosiphile and Palanee-Phillips, Thesla and Panchia, Ravindre and Pillay, Saresha and Potloane, Disebo and Selepe, Pearl and Singh, Nishanta and Singh, Yashna and Spooner, Elizabeth and Ward, Amy M and Zwane, Zwelethu and Ebrahimi, Ramin and Zhao, Yang and Kintu, Alexander and Deaton, Chris and Carter, Christoph C and Baeten, Jared M and Matovu Kiweewa, Flavia and PURPOSE 1 Study Team, PURPOSE 1 Study Team},
  title = {Twice-Yearly Lenacapavir or Daily F/TAF for HIV Prevention in Cisgender Women},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {13},
  pages = {1179--1192},
  doi = {10.1056/nejmoa2407001}
}
Kostenlos starten →